SAN FRANCISCO, June 14 /PRNewswire/ -- Stem Cell Sciences plc (SCS), the first scientific team to prove therapeutic cloning is possible in mammalian species, today acknowledged two reports, by academic scientists from the University of Edinburgh and Massachusetts Institute of Technology (MIT), which validate proprietary SCS technologies for improving the efficiency of therapeutic cloning, or so-called “cell reprogramming.”
